We are live on ! Find out more
ABEO icon

Abeona Therapeutics

100 hedge funds and large institutions have $188M invested in Abeona Therapeutics in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

322% more call options, than puts

Call options by funds: $8.67M | Put options by funds: $2.06M

58% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 24

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

5% more funds holding

Funds holding: 95100 (+5)

1.17% more ownership

Funds ownership: 68.23%69.4% (+1.2%)

5% less capital invested

Capital invested by funds: $198M → $188M (-$10.3M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
19
Increased
38
Reduced
24
Closed
14
Calls
$8.67M
Puts
$2.06M
Net Calls
+$6.62M
Net Calls Change
-$5.63M
Name Holding Trade Value Shares
Change
Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$24.1M +$1.24M +195,000 +4%
BlackRock
2
BlackRock
New York
$16.6M +$939K +147,996 +5%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$16.1M -$159K -25,000 -0.8%
SCM
4
Suvretta Capital Management
New York
$14.1M
Vanguard Group
5
Vanguard Group
Pennsylvania
$13.7M +$608K +95,878 +4%
VC
6
Vivo Capital
California
$9.73M
WSL
7
Western Standard LLC
California
$6.6M -$5.34M -841,641 -40%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$5.95M +$135K +21,269 +2%
KCM
9
Kennedy Capital Management
Missouri
$5.55M +$2.4M +378,860 +56%
SCM
10
Silverarc Capital Management
Massachusetts
$5.25M +$487K +76,856 +8%
PBM
11
Propel Bio Management
California
$5.14M
Bank of America
12
Bank of America
North Carolina
$4.82M +$3.7M +583,028 +177%
6CM
13
683 Capital Management
New York
$4.07M +$127K +20,000 +3%
State Street
14
State Street
Massachusetts
$3.78M +$826K +130,274 +22%
Millennium Management
15
Millennium Management
New York
$3.75M +$2.87M +452,334 +176%
Morgan Stanley
16
Morgan Stanley
New York
$3.21M -$2.29M -361,635 -37%
CCC
17
Cable Car Capital
California
$3.17M +$3.81M +600,000 New
SAM
18
Simplify Asset Management
Nevada
$2.98M +$40.7K +6,425 +1%
NFT
19
Nan Fung Trinity
Hong Kong
$2.96M
AIC
20
AWM Investment Company
New York
$2.89M +$488K +77,000 +16%
Renaissance Technologies
21
Renaissance Technologies
New York
$2.78M +$1.44M +226,500 +76%
Citigroup
22
Citigroup
New York
$2.77M -$153K -24,101 -4%
BCM
23
Boone Capital Management
Georgia
$2.66M -$4.77M -751,804 -60%
SCM
24
Stonepine Capital Management
Oregon
$2.38M +$2.57M +405,970 +902%
Northern Trust
25
Northern Trust
Illinois
$2.23M -$76.1K -11,995 -3%

ABEO Hedge Fund Activity: Q3 2025 in Review

100 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2025, worth a combined $188M — down 5.2% from $198M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ABEO positions and 14 closed out — a net gain of 5 holders — while 38 added to existing stakes and 24 trimmed.

The largest buyer was Cable Car Capital, opening a new position worth an estimated $3.81M. The largest seller was Western Standard LLC, cutting an estimated $5.34M.

  • 100 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2025, up from 95 in Q2 2025.
  • Funds reported $188M of Abeona Therapeutics stock for Q3 2025, down 5.2% quarter-over-quarter.
  • 19 funds opened new Abeona Therapeutics positions in Q3 2025 and 14 closed out, a net change of +5 holders.
  • The largest Abeona Therapeutics buyer in Q3 2025 was Cable Car Capital, an estimated $3.81M added.
  • The largest Abeona Therapeutics seller in Q3 2025 was Western Standard LLC, an estimated $5.34M sold.

Based on aggregated 13F filings for Q3 2025.